logo
Sign in

SQZB Stock Price, Chart, Stats & News

SQZ Biotechnologies Company
Save

SQZ Biotechnologies Company (SQZB) does not currently pay a dividend.

707,787
Market cap
Current P/E
Forward P/E

SQZB chart

1M
3M
1Y
5Y
Loading chart...

About

Health care
Sector
Biotechnology
Industry

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents.

Similar securities

Based on sector and market capitalization

Report issue